Trial
NCT01147393
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Gilead Sciences
Condition
Follicular Lymphoma
Intervention
90Y-epratuzumab tetraxetan
Why stopped
closed to enrollment due to slow patient accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-22